Some kinases (e.g. PRKACA, CSNK2A1 and MAPK1) were found specifically dysregulated across multiple tumour types, but more than half were dysregulated in just one tissue (68%) such as MYLK kinase in stomach cancer and MTOR in kidney cancer (Appendix Fig S10D). This evidence concerns the gene MYLK and neoplasm.